DE
News & Events

London (    UK), February 12, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company  pioneering a groundbreaking new way of treating cancer, today announces it has received a notification from the United States Patent and Trademark Office (USPTO) stating that a patent for the manufacturing process of Vidac’s lead therapeutic candidate VDA-1102 for actinic keratosis (AK) and cutaneous T-cell lymphoma (CTCL) will issue from Vidac’s application as of 20 February, 2024. Under US law, the patent term is 20 years, with an additional 823 days granted in this case, meaning the US patent will expire on 8 April, 2041.

“The US patent to protect the manufacturing of VDA-1102 is an important step towards commercialization. Our lead asset is a non-toxic agent to fight actinic keratosis and cutaneous T-cell lymphoma, for which we recently reported positive Phase 2a interim results. The news also bodes well for other members of our family of small molecules, such as VDA-1275, which is currently undergoing pre-clinical testing for a wide range of solid tumors,” said Prof. Max Herzberg, Chief Executive Officer of Vidac Pharma.

Vidac Pharma is developing a breakthrough new technology which reverses the abnormal metabolism of cancer cells by preventing the Hexokinase 2 (HK2) enzyme from blocking the VDAC mitochondrial relay channels. Clinical data have shown the powerful effects this can have in halting cancer cell proliferation and immune-resistance, and restoring programmed cell death. Vidac Pharma last month reported interim Phase 2a results for VDA-1102 in CTCL that compared favorably to the standard of care and the company is about to launch a Phase 2b study for VDA-1102 for AK, the other indication for which this drug candidate is being tested, selecting patients with an advanced stage of the disease, in which VDA-1102 has shown to be more effective.

 

For more information please contact:

 

Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/

investors@vidacpharma.com
+972-54-4257381
+972-77-9300647

Cohesion Bureau
Giovanni Ca’ Zorzi
Investor Relations
giovanni.cazorzi@cohesionbureau.com

Sophie Baumont

Media Relations 

sophie.baumont@cohesionbureau.com

 

 

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK) and is also being tested in Cutaneous T-cell Lymphoma (CTCL) in Phase 2 trials in humans.
www.vidacpharma.com

Important information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.